A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
NCT02616302
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
70
Enrollment
INDUSTRY
Sponsor class
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
DRUG:
Dexlansoprazole
Sponsor
Takeda